Subjective endpoints in clinical trials: the case for blinded independent central review
Richard Walovitch,1 Bin Yao,2 Patrick Chokron,1 Helen Le,1 Glenn Bubley3 1WorldCare Clinical, LLC, Boston, MA, USA; 2Amgen, Inc, Thousand Oaks, CA, USA; 3Director of Genitourinary Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA Abstract: Primary efficacy and safety endpoints...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-09-01
|
| Series: | Open Access Journal of Clinical Trials |
| Online Access: | http://www.dovepress.com/subjective-endpoints-in-clinical-trials-the-case-for-blinded-independe-a14484 |